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ABSTRACT
Autosomal recessive osteopetrosis (ARO) is a genetically heterogeneous disorder attributed to reduced bone resorption by osteoclasts.
Most human AROs are classified as osteoclast rich, but recently two subsets of osteoclast-poor ARO have been recognized as caused by
defects in either TNFSF11 or TNFRSF11A genes, coding the RANKL and RANK proteins, respectively. The RANKL/RANK axis drives
osteoclast differentiation and also plays a role in the immune system. In fact, we have recently reported that mutations in the TNFRSF11A
gene lead to osteoclast-poor osteopetrosis associated with hypogammaglobulinemia. Here we present the characterization of five
additional unpublished patients from four unrelated families in which we found five novel mutations in the TNFRSF11A gene, including
two missense and two nonsense mutations and a single-nucleotide insertion. Immunological investigation in three of them showed that
the previously described defect in the B cell compartment was present only in some patients and that its severity seemed to increase
with age and the progression of the disease. HSCT performed in all five patients almost completely cured the disease even when carried
out in late infancy. Hypercalcemia was the most important posttransplant complication. Overall, our results further underline the
heterogeneity of human ARO also deriving from the interplay between bone and the immune system, and highlight the prognostic and
therapeutic implications of the molecular diagnosis.  2012 American Society for Bone and Mineral Research.
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Introduction
A
utosomal recessive osteopetrosis (ARO) is a rare genetic
bone disease characterized by increased bone density
because of failure in bone resorption. Two main forms can be
distinguished on the basis of the presence or absence of
osteoclasts, as assessedthroughbonebiopsy,whenavailable.
(1,2)
In the osteoclast-rich form, which comprises the large majority of
ARO cases, a normal to high number of mature, nonfunctional
osteoclasts is present, whereas in the osteoclast-poor form these
specialized cells are absent because of a defect in osteoclast
differentiation. Two genes have been involved so far in the
pathogenesis of this latter form in humans, namely, TNFSF11
(RANKL) and TNFRSF11A (RANK).
(3,4) In bone, the TNFSF11 gene
encodes the main osteoclast differentiation factor produced
by osteoblasts and stromal cells, while its receptor, RANK, is a
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342transmembrane protein expressed on the surface of preosteo-
clasts and mature osteoclasts.
(5) Therefore, the osteoclast defect
is cell autonomous in the case of TNFRSF11A mutations, but
is noncell autonomous when RANKL production is defective.
This diverse pathogenesis explains the differing behavior of
the two subsets of osteoclast-poor ARO patients; osteoclast
precursors derived from RANKL-ARO patients are able to
differentiate in vitro after exposure to M-CSF and RANKL,
but the patients do not respond to hematopoietic stem cell
transplantation (HSCT) in vivo, whereas for the RANK-ARO
patients, the opposite is true.
(2–4)
Interestingly, the RANK receptor can activate several signaling
pathways, which are functional not only in the osteoclast lineage
but in other tissues as well, including immune cells, as shown by
the immunological phenotype displayed by both Tnfsf11
 /  and
Tnfrsf11a
 /  mice dominated by absence of lymph nodes.
(6–10)
However, no major immunological defects have been identified
in RANKL-deficient patients,
(3) whereas a partial defect in
peripheral B cell maturation, sometimes associated with a mild
hypogammaglobulinemia, was reported in RANK-deficient
patients by our group.
(4) Nevertheless, the results of immuno-
logical investigations previously performed on RANK-dependent
ARO should be regarded as preliminary, because of the difficulty
in obtaining adequate material from patients affected by this
very rare pathology.
Because the description of RANK-ARO patients is limited to
the original report,
(4) these issues need further analysis. We
report here the identification of five previously unpublished
RANK-dependent ARO patients bearing a total of five novel
mutations. A detailed characterization of their clinical history
showedanincreasingheterogeneityinthisraresubgroupofARO
patients.
Materials and Methods
Mutation analysis
Specimens, including blood and DNA samples, were collected
from patients after their parents provided informed consent.
Clinical, radiological, and laboratory data were collected for
genotype–phenotype correlation studies. This research complies
with the standards established by the local Ethical Committee
and the granting agency.
Sequence analysis of the TNFRSF11A gene (transcript ID
number NM_003839) was performed as previously described.
(4)
In the case of new missense mutations, at least 100 chromo-
somes from normal unrelated donors from the same geographi-
cal area were also investigated by direct sequence analysis.
In vitro differentiation of human osteoclasts and confocal
microscope analysis
Human osteoclasts were generated by culture of peripheral
blood monocytes with M-CSF and RANKL using a standard
protocol. Peripheral blood mononuclear cells (PBMCs) were
isolated from heparinized blood samples by Ficoll density
gradient centrifugation (Biochrom, Cambridge, UK). PBMCs were
cultured either on glass coverslips for differentiation analysis or
on dentine discs for resorption assays in alpha MEM (Lonza,
Walkersville, MD, USA), 10% FCS (Gibco, Grand Island, NY, USA),
1% Ultraglutamine (Lonza), 1% Pen/Strep, 25ng/mL human M-
CSF(R&D,Minnespolis,MN,USA),and30ng/mlRankl(Peprotech,
Rocky Hill, NJ,USA). Cellswerecultured for2weeks with medium
changes twice weekly. Cells on coverslips were fixed in 4%
paraformaldehyde (PFA) in 1  phosphate-buffered saline (PBS)
and then stained with Phalloidin-Alexa 488 (Molecular Probes,
Eugene, UT, USA), DAPI (Molecular Probes), and tartrate-resistant
acid phosphatase (TRAP) activity using Naphtol-AS-MX-Phos-
phate (Sigma, St. Louis, MO, USA) and Fast-Red-Violet LB (Sigma).
TRAP-positive cells with  3 nuclei and actin rings were counted
as osteoclasts. Dentine discs were cleaned with 1% SDS and
resorption pits were visualized by black ink.
Expression analysis
Osteoclasts were lysed in Trizol (Invitrogen, Carlsbad, CA, USA) at
day 14 of culture. After mRNA isolation according to the protocol
provided by the manufacturer, cDNA synthesis was performed
using the Revert Aid kit (Fermentas, Hanover, MD, USA) and
random hexamers. Quantitative PCR was performed using the
Taqman 7500 Real-Time PCR System (Applied Biosystems,
Bedford, MA, USA) and the SYBR Green reagent (Applied
Biosystems). TNFRSF11A- and GAPDH-specific primers were used
for target gene and endogenous control amplification, respec-
tively.Primer sequences are availableon request. RQ values were
calculated by the SDS software (Applied Biosystems).
Enzyme-linked immunosorbent spot
Plasma cells secreting IgG, IgM, or IgA were detected using an
enzyme-linked immunosorbent spot assay. Briefly, 96-well plates
(Millipore, Bedford, MA, USA) were coated with 10mg/mL
purified goat antihuman IgG, IgA, IgM (SouthernBiotech,
Birmingham, AL, USA). After washing and blocking with PBS
containing 1% (w/v) bovine serum albumin for 30minutes,
serial dilutions of peripheral blood (PB) or bone marrow (BM)
mononuclear cells were added and incubated overnight at 378C.
Plates were then washed and incubated with isotype-specific
secondary antibodies, followed by streptavidin–horseradish
peroxidase (Sigma-Aldrich, St. Louis, MO, USA). The assay was
developed with 3-amino-9-ethylcarbazole (Sigma-Aldrich) as a
chromogenic substrate.
Flow-cytometry analysis
For patients 8A and 8B the immunological characterization was
carried out at Ho ˆpital Necker-Enfants Malades (Paris, France).
Peripheral blood mononuclear cells were stained with APC anti-
CD19, FITC anti-CD27, PE anti-IgD (all from BD Biosciences
Pharmingen, San Diego, CA, USA) and Biotin anti-IgM (Jackson
ImmunoResearch, West Grove, PA, USA). Percentages of CD27
þ
and switched (CD19
þ/IgD
 /CD27
þ) B cells were determined
by gating on CD19
þ and CD19
þ/CD27
þ B cells, respectively. The
analysis was performed with FACScalibur (Becton Dickinson,
Fullerton, CA, USA).
For patient 9 the immunological characterization was carried
out at the Istituto Clinico Humanitas (Milan, Italy). Mononuclear
cellsfromthePBandBMofthepatientwerepurifiedbystandard
density gradient technique and labeled with the following
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anti-CD21, APC anti-CD27, FITC anti-IgM, FITC anti-IgD (BD
Biosciences Pharmingen). Samples were acquired on a FACS-
Canto II system (BD Pharmingen) and analyzed with FLOWJO
software (version 4.5.4; Tree Star Inc., Ashland, OR, USA).
Results
Genetic findings
FivenewRANK-dependentAROpatients(seenextsectionforthe
clinical findings) were screened for genes responsible for human
ARO. This led to the identification of biallelic mutations in
the TNFRSF11A gene in each patient, for a total of five novel
mutations (shown in red and magenta in Fig. 1): two missense,
two nonsense, and a single-nucleotide insertion.
Patient 8A washomozygous forac.443A>T mutation causing
a p.Asp148Val amino acid change and his consanguineous
parents were heterozygous for the same nucleotide change.
Subsequently we analyzed his affected double first cousin
(patient 8B; the family pedigree is shown in Supplementary
Fig. 1) and, as expected, found the same mutation at the
homozygous state.
Patient 9 was homozygous for the single nucleotide insertion
c.328_9insC leading to frameshift and premature termination
(p.Arg110ProfsX52). The same mutation was found in the
heterozygous state in her consanguineous parents.
Patient 10 was homozygous for a transition (c.401C>T)
leading to a novel missense mutation (p.Ala134Val); both her
consanguineous parents were heterozygous for this nucleotide
change.
Patient 11 was a compound heterozygote for two transver-
sions, c.247G>T and c.372C>A, causing a stop at codon 83
(p.Glu83X) and 124 (p.Cys124X), respectively. His father was
heterozygous for the first mutation and his mother for the
second one.
Fig. 1. Mutations in relation to the RANK protein structure. (A) Three-dimensional model of extracellular domain of human RANK protein. The mutations
found to date, in this domain, in our patients are depicted as follows: mutations previously published
(4) are in blue, novel missense mutations are in
magenta, novel nonsense and frameshift in red. Human RANK three-dimensional protein structure was determined by homology modeling using the
protein structure of mouse rank (downloadable from www.rcsb.org:3ME4.pdb) as a template. Modeling was performed by means of SWISS-MODEL tools
(http://swissmodel.expasy.org/)onthebasisoftheCLUSTALWalignmentbetweenhumanRANKprimarysequenceastargetprotein,(NP003830.1)andthe
3ME4 mouse rank template. Model quality assessment tools were used to estimate the reliability of the resulting model. (B) Alignment of RANK protein
sequences from several species in the regions covering the missense mutations identified. The mutated residues are indicated above the sequences. The
corresponding residues in the individual sequences are colored, missense mutations previously published in blue, novel missense mutations in magenta.
The graphical view of domain structure was obtained by ProtoNet (automatic hierarchical classification of protein sequences).
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were not found in more than 100 chromosomes from healthy
unrelated individuals from the same geographical areas
and therefore are unlikely to be neutral polymorphisms.
Alignment of RANK protein sequences from several species
further supports this idea, because the mutated residues
are strongly conserved in evolution (Fig. 1B). Both amino
acid substitutions fall in the extracellular domain of the
receptor and are likely to affect the binding to the ligand. The
two nonsense mutations and the insertion are predicted to lead
to the production of N-terminally truncated forms of RANK
protein, lacking the entire transmembrane and intracellular
domains.
Clinical evaluation of patients
We reviewed the clinical history of these new RANK-dependent
patients in order to better define the features of this subset of
ARO (Table 1).
Patient 8A is the first child of consanguineous Kurdish parents
(Supplementary Fig. 1). He was treated at 1 month of age for
severe gastrooesophageal reflux. At the age of 6 months, he
presented with noisy breathing. X-rays documented increased
bone density of the skull base, diffuse osteosclerosis, and
multiple signs of previously unrecognized fractures in X-rays
of the complete skeleton consistent with the diagnosis of
osteopetrosis. At that time, no hematological anomalies or
hypocalcemiawerenoted. Furthermore, visual evokedpotentials
(VEPs) were reported to be completely normal at the age of
7 months, so that no indication for hematopoietic stem cell
transplantation (HSCT) was thought to be present. However,
from the age of 8 months, rapid deterioration of the vision was
observed, leading to almost complete blindness at the age of
10 months as documented by the absence of VEPs. A magnetic
resonance imaging (MRI) scan at 15 months of age confirmed
bilateral narrowing of optic nerve foramina with important nerve
compression. Therefore, the decision to perform HSCT was taken
(see HSCT and Follow-up), supported by the result of the genetic
analysis showing the presence of a homozygous mutation
in the TNFRSF11A gene. Interestingly, this patient did not
show important hematological impairment besides a moderate
anemia (at 21 months of age, before HSCT, hemoglobin was
8.6g/dL with a mean corpuscular volume of 63 fl), while he
developed important splenomegaly (122mm), hepatomegaly
(95mm), and mild thrombocytopenia (113 10
9 platelets/L).
His double first cousin, patient 8B, was investigated soon after
birth because of the positive family history. He presented with
asymptomatic hypocalcemia at birth (total calcium 1.52mmol/L
with 0.80mmol/L ionized calcium); subsequent radiological
investigations showed diffuse sclerosis of skull and spine and
abnormal bone modeling of long bone metaphyses. Genetic
analysis confirmed the presence of the same homozygous
mutation found in his cousin. At 5 months of age he received
HSCT (see HSCT and Follow-up). No visual impairment was
documented and only a moderate anemia was reported (Hb
8.7g/dL, 75 10
9 reticulocytes/L, 283 10
9 platelets/L, 10.2 
10
9leucocytes/L, 1.4 10
9 neutrophils/L, beforeconditioning for
HSCT). A careful immunological characterization of patients 8A
and 8B was carried out before transplantation (see Immunologi-
cal Investigations).
Patient 9 is the first child of consanguineous parents from the
Black Forest, Germany. She was referred to us for molecular
investigation when she was already 10 and was described as
an unusual case of osteopetrosis presenting a severe bone
phenotype with important jaw and skull deformations and
multiple fractures, congenital blindness, but nearly no im-
pairment of hematopoiesis. The bone biopsy showed highly
mineralized bone tissue and irregular net-like trabecular
structure. Intertrabecular spaces were scarce and showed
neither adipocytes nor islands of hematopoiesis. Osteoclasts
were not detected using conventional staining methods
(Supplementary Fig. 2). At the age of 12 years, the clinical
status of the patient worsened, with the appearance of
hematological symptoms, osteomyelitis of the maxilla, and deep
apnoeaphasesbecauseofdeformitiesofthejawbonesrequiring
tracheostomy. Therefore, supported by the result of the
mutational analysis, HSCT was performed. As in patients 8A
and 8B, immunological investigations were carried out before
transplantation (see Immunological Investigations).
Patient 10 is the first child of consanguineous parents
from Pakistan. She was investigated from the neonatal period
onwards because of hypocalcemia, poor feeding, hypotonia,
subclinical seizures, and respiratory acidosis. She was noted to
have a significant gastrooesophageal reflux. She later developed
a bulbar palsy (confirmed on EMG) and a right intraventricular
hemorrhage. Skeletal X-rays revealed a generalized increase in
bone density with loss of corticomedullary differentiation and
abnormal appearance of metaphyses, in addition to a minimally
displaced fracture of the distal left ulna. She had two episodes of
right-sided weakness, considered to be of vascular origin but no
abnormality was found on an MRI in the left hemisphere. When
she was 19 months old, her vision was noted to be deteriorating
and an MRI scan showed increased intracranial pressure;
she therefore underwent ventriculostomy at 23 months. After
a transient improvement, her vision worsened again and she
had a VP shunt inserted. This significantly improved her feeding
problems but did not restore vision and flash VEPs have shown
only background noise ever since. Sleep studies, performed
when she was 24 months old, showed severe obstructive sleep
apnoea. Despite the very early onset of the bone phenotype,
the child developed only moderate anemia and no hepato-
splenomegaly.
Patient 11 was referred to us for molecular diagnosis after
HSCT was performed at 11 months of age. Overall, compared
with the other patients here reported, he had a more classical
clinical presentation. He was the second child of unrelated
parents. At the age of 2 months he was noted to be
macrocephalic and there were also concerns regarding his
vision. An MRI scan showed hydrocephalus, requiring the
insertion of a VP shunt, and bilateral optic atrophy associated
with complete visual loss. He was also found to have moderate
hepatosplenomegaly and anemia. A skeletal survey showed
appearance of bone typical of ARO but without obvious signs
of fractures. The child had also a number of gastrointestinal
problems including gastrooesophageal reflux, lactose intoler-
ance, and failure to thrive.
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Cells for the osteoclast differentiation assay were available only
for patient 9. Because she had not yet been transplanted at
10 years of age, we were able to obtain several samples and
the assay was carried out in parallel in different laboratories.
Of note, the analysis of in vitro osteoclast differentiation was
double blind with respect to the result of the molecular analysis
ofthispatient. TNFRSF11A mutationspreviouslyidentifiedinARO
patientscorrelated,asexpected,withtheinabilitytodifferentiate
osteoclast precursors in vitro after exposure to M-CSF/RANKL,
because the defect is cell-autonomous.
(4,11)
Unexpectedly,atvariancewiththeseresults,invitroosteoclast
differentiation from patient 9 showed the formation of a
number of TRAP-positive multinucleated cells in the presence of
macrophage-colony stimulating factor (M-CSF) and RANKL
(Fig. 2A). These cells, however, failed to resorb bone, when
cultured on dentin (Fig. 2B), in agreement with the osteopetrotic
phenotype of this patient.
The possibility that the RANKL/RANK pathway could maintain
partial activity in this patient was considered. Quantitative
reverse transcription-polymerase chain reaction (RT-PCR)
revealed that, despite the early stop codon induced by the
frameshift mutation, the mRNA isolated from cultured osteo-
clasts was not subjected to nonsense-mediated decay (Fig. 2C).
To further verify this hypothesis, cultures of M-CSF-dependent
macrophages derived from patient 9 and a healthy donor were
stimulated with RANKL or tumor necrosis factor (TNF)-a (as a
control) for up to 20minutes and analyzed for NFkB-p65
translocation. The cells responded to treatment with TNF-a as
expected. When treated with RANKL, the patient cells did show a
time-dependent increase in the percentage of cells with nuclear
p65, although not as pronounced as in cultures of cells from the
healthy donor (data not shown). These data suggested that
partial RANKL-dependent NFkB activation in cells from this
patient was present in vitro, although these experiments could
not be confirmed because of lack of available material from
patient 9, who had undergone transplantation in the meantime.
Immunological investigations
Because genetic defects in the TNFRSF11A gene have been
previously linked to an impairment in peripheral B cell
maturation in some patients,
(4) in three new RANK-dependent
patients whose pre-HSCT blood cells were available we
performed an immunological characterization of the B cell
compartment using markers CD19, IgD, and CD27. In this way
three subpopulations can be identified: naı ¨ve B cells, defined as
CD19
þ/IgD
þ/CD27
 , representing the bulk of the circulating and
resident follicular B cells that have never been exposed to
antigens; memory B cells (CD19
þ/IgD
þ/CD27
þ), representing a
primitive low affinity type of cell; switched memory B cells
Fig. 2. Osteoclast differentiation and function for patient 9. (A) Fluorescence images of osteoclasts cultured on glass coverslips, generated from PBMCs of
patient 9 and one healthy donor (HD), in concurrent cultures in the presence of M-CSF and RANKL. Osteoclasts were stained for tartrate-resistant acid
phosphatase (TRAP) activity (red); actin (green); nuclei were stained with DAPI (blue). Scale bar¼100mm. Bar graph reports the percentage of TRAP-
positivemultinucleated(morethanthreenucleipercell)cellsinpatient9andinthehealthydonor.Resultsaretheaverageofthreecultures.Thevaluesare
notsignificantlydifferent.(B)Resorptionassayforosteoclastsfrompatient9andhealthydonorculturedondentinediscfor14days.Pitswerevisualizedby
ink staining. Representative discs are shown. HD cells showed resorption in five of six dentine discs whereas no pits were detected in all six of patient9
dentinediscs. Scale bar¼1mm. (C) Quantitative RT-PCR of TNFRSF11A mRNA expression in cultured osteoclasts. No reduced expression of RANK could be
detected in patient 9cells compared with HD. Results are the average of three cultures.
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þ/IgD
 /CD27
þ), which are the effectors of the high affinity
adaptive response, giving rise to the long-living plasma cells.
In agreement with our previous findings, in the two cousins
here described, patient 8A and 8B, the cytofluorimetric analysis
revealedareductioninswitchedmemoryBcells(IgD
 /CD27
þ)in
the periphery even though less pronounced than in the two
siblings reported before (Fig. 3). The milder defect in patients 8A
and 8B could be because of their younger age as compared
with patients 1A and 1B;
(4) in fact, the percentage of switched
memory B cells is known to increase with age.
(12)
On the contrary, the analysis of circulating B cells from patient
9 with CD19, CD27, and IgD markers indicated a frequency of
mature (CD27
þ) and switched (CD19
þ/IgD
 /CD27
þ) B cells
similar to that observed in age-matched healthy control (Fig. 4A).
Examination of B cell development in the bone marrow
revealed a reduced frequency of early-immature B cell subsets
but rather normal to increased percentages of naı ¨ve and
memory B cells with respect to the control (Fig. 4B). Moreover,
ELIspot analysis showed, in patient 9 and in the healthy donor,
similar frequencies of immunoglobulin-secreting cells in the
peripheral blood and bone marrow, either producing IgM or IgG/
A (Fig. 4C). Consistent with these findings, the patient’s global Ig
levels were in the normal range (Table 1), as well as specific
antibody titers against live vaccination.
HSCT and follow-up
All the patients received HSCT. Myeloablative conditioning,
prevention of veno-occlusive disease (VOD) and prophylaxis of
graft-versus-host disease (GVHD) were performed according to
the European Group for BoneMarrow Transplantation–European
Society for Immunodeficiencies (EBMT-ESID) guidelines.
Patient 8A was transplanted at 21 months of age with
peripheral stem cells from a matched unrelated donor (10/10)
without T cell depletion. For prophylaxis of GVHD Cyclosporin A
wasreplacedby corticosteroids atday þ16 becauseofimportant
hypercalcemia. Myeloid engraftment occurred on day þ15,
platelet counts and red blood cell counts rapidly normalized
(last transfusion on day þ10 and on day þ29, respectively).
Full donor engraftment was achieved. Severe hypercalcemia
(plasma calcium level up to 4.02mmol/L and ionized calcium
2.13mmol/L at day þ18) required hyperhydration, diuretics,
corticosteroids, bisphosphonates, and calcitonin for several
weeks. Two months after HSCT the patient developed
nephrocalcinosis; however, renal function could be completely
restored. Besides hypercalcemia, the post-HSCT course was
uneventful and favorable. The patient is alive and well, without
any specific treatment, at the last follow-up 18 months after
HSCT. He presents no developmental delay in his motor
milestones and his mental development is very satisfying with
regard to language and understanding; however, no obvious
improvement in visual ability occurred. The first teeth were
delayed in their eruption: the patient had 11 teeth at the age
of 33 months.
Patient 8B received an HLA-identical family donor HSCT at
5 months of age. Myeloid engraftment occurred on day þ21,
platelet counts and red blood cell counts rapidly normalized.
At engraftment, donor chimerism was 95%. Ionized calcium
was at maximum 1.48mmol/L at day þ20, hypercalcemia was
rapidly regressing under hyperhydration. At day þ8, the patient
presented very mild signs of VOD, evolution was rapidly
favorable. At day þ46, the patient had to be transferred to
the pediatric intensive care unit for acute respiratory failure
because of Pneumocystis pneumonia and suprainfection with
Klebsiella pneumoniae. The course was favorable under adequate
antiinfectious therapy. The patient was dismissed 3 months after
HSCT and is alive and well at the last follow-up 6 months after
HSCT.
Fig. 3. Analysis of B cell compartment in patients 8A and 8B. Percentage of naive (IgD
þ/CD27
 ), memory (IgD
þ/CD27
þ) and switched memory B cells
(IgD
 /CD27
þ) in patients 8A and 8B (21 and 5 months old at analysis, respectively) herein described in comparison with patients 1A and 1B (6 and 3 years
old at analysis, respectively) previously described by our group.
(4) As a control, the percentages of healthy donors (HD groups) of the corresponding
age group
(12) for each patient are reported.
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transplantation at 12 years of age. Full donor engraftment was
associated with severe hypercalcemia (plasma calcium level up to
4.2mmol/L) requiring hemodialysis, bisphosphonates, calcitonin,
and finally anti-RANKL antibody, which resulted in normalization
of plasma calcium levels (manuscript in preparation). About
12 months after transplantation she was discharged from hospital.
About 15 months after transplantation, she is in very good mental
condition, her bloodcell counts and her serumcalcium levels have
normalized. The tracheostomy is still in place and immunosup-
pressive treatment for limited chronic GVHD and antimicrobial
treatment because of osteomyelitis of the jaw are ongoing.
Patient 10 received a matched unrelated donor (10/10) stem
cell transplant at the age of 3 years, achieving full donor
engraftment. Six weeks after transplantation she developed
cyclosporine-induced posterior reversible encephalopathy
(PRES), so calcineurin inhibitor was stopped and replaced with
Sirolimus and steroids to prevent GVHD. Two months after
transplantation she presented persistent hypercalcemia (maxi-
mum level 5mmol/L) treated unsuccessfully with hemofiltration.
Plasma calcium level normalized after receiving anti-RANKL
antibody (manuscript in preparation). The patient also devel-
oped respiratory distress and oxygen desaturation because of a
combination of upper respiratory obstruction and aspiration
pneumonia. A tracheostomy was performed and the patient
is still on continuous positive airway pressure (CPAP) support,
4 months after transplantation.
Patient 11 underwent a matched sibling donor bone marrow
transplantation at the age of 11 months. The transplant
procedure and posttransplant recovery period was uncompli-
cated, with only mild hypercalcemia (maximum level 3.39mmol/
L) not requiring specific intervention. The child achieved full
donor engraftment and a good immune reconstitution. Eight
months post-HSCT he developed diarrhoea for which he had
biopsies, suggesting an eosinophilic enterocolitis treated with
CetirizineandSodiumCromoglycate.Becauseofalackofinterest
in feeding the patient eventually had a gastrostomy inserted at
about 10 months post-HSCT, with subsequent weight gain. He
hadaskeletalsurvey19monthspost-HSCTand,comparedwitha
pre-HSCTstudy, bones showedsatisfactory improvement intheir
structural appearances. He is now 3 years post-HSCT, at home
and reasonably well. He has a mild developmental delay
especially in his motor milestones; his sleep is disturbed and
unpredictable.
Fig. 4. AnalysisofBcellcompartmentinpatient9.(A)Peripheralbloodmononuclearcellsfrompatient9andarepresentativeage-matchedhealthydonor
(HD) were stained with anti-CD19, -CD27, and IgD mAbs and analyzed by flow cytometry. FACS plots are gated on CD19
þ cells. Numbers indicate
percentage of cells for each subset. (B) BM-derived mononuclear cells from patient 9 and a healthy donor were stained with anti-CD19, -CD24, and -CD38
mAbs. FACS plots shown are gated on CD19
þ cells. Numbers indicate percentage of cells for each subset. (C) Frequency of Ig-secreting cells (IgM and
IgG-IgA isotypes) in cultures for patient 9 (black) and from a healthy donor (white). The number of spots/10
5 CD19
þ B cells is reported.
Journal of Bone and Mineral Research NEW RANK-DEPENDENT ARO PATIENTS 349Discussion
Autosomal recessive osteopetrosis is a rare genetic bone disease
in which the main feature, increased bone density, is due to
either the presence of nonfunctional osteoclasts (in the
osteoclast-rich forms) or to their absence (in the osteoclast-
poor forms). In humans these latter represent a very limited
group which has been identified only very recently.
(3,4,13,14) At
least two genes, TNFSF11 and TNFRSF11A, are involved in their
pathogenesis. In the present work we report the clinical and
molecular characterization of five new patients affected by
osteoclast-poor ARO, because of novel mutations in the
TNFRSF11A gene. In our cohort of more than 250 ARO, RANK-
dependentpatientsconstitutealmost5%,andtoourknowledge,
noothercasesofthissubgrouphavebeendescribed.Overall,the
clinical phenotype of the five new patients closely resembled
that of the RANK-dependent ARO we have previously described;
they presented with a classical osteopetrotic bone appearance
and a variability of fracture incidence; blindness was present in
four out of five patients and other secondary neurological
defects were reported in two. On the basis of the phenotype of
Tnfrsf11a
 /  mice and of our previous preliminary observation
suggesting a primary immunological defect in RANK-dependent
ARO, we performed immunological investigations in three
patients, mainly focused on the B cell compartment.
Our results suggest that the degree of immunological
impairment of RANK-ARO patients is variable. In patient 9 a
low number of B cells was present in the periphery compared
with the corresponding healthy donor; however, we could not
findamajordefectinBcellmaturationasconfirmedbynormalIg
levels. Onthe contrary, patients8A and8B showedareduction in
switched memory B cells, even though less pronounced than
in patients 1A and 1B from our previous work, suggesting that
the defect could worsen with age or the progression of the
disease.ThevariabilityinIglevelscouldbeexplainedinthesame
way, even though further investigation is required to clarify this
aspect. Interestingly, low IgG levels have also been recently
reported in a few TCIRG1-dependent ARO.
(15)
All five patients were transplanted and in three of them the
bone defect was rescued, while bone remodelling is still ongoing
in patients 8B and 10. The favorable outcome of HSCT further
confirms the appropriateness of this therapeutic approach in
RANK-dependent ARO, but as expected, it cannot restore the
visualcapacityiftheopticalnerveisalreadydamagedatthetime
of transplantation. This fact emphasizes the essential role of
molecular diagnosis and highlights that RANK-patients should
be transplanted as early as possible, despite the absence of
severe hematological features, in order to prevent visual loss.
Of note, patient 9 is, to our knowledge, the only ARO patient
transplanted late in childhood (12 years compared with a mean
age of 10.3 months and 6 months in 2 different reports);
(15,16)
however, HSCT was successful with persistent severe hypercal-
cemia as the only side effect. Hypercalcemia is a well-known
post-HSCT complication in ARO,
(16–19) but in the RANK-
dependent patients here reported, it seems to have a higher
prevalence and a longer persistence, requiring more aggressive
treatments. Acorrelation wassuggested betweenhypercalcemia
and age at HSCT,
(16,19) leading to the hypothesis that larger bone
mass in older patients could result in a higher and longer release
of calcium stored in the osteopetrotic bones by donor-derived
osteoclasts activity. Indeed, RANK-dependent patients received
HSCT later in life, owing to a milder hematological involvement,
compared with classic TCIRG1-dependent osteopetrosis. Anoth-
er explanation might be that in RANK-dependent patients,
TNFSF11 may be compensatorily overexpressed, leading to a
highly activated RANKL-RANK system which, after transplant,
may generate a rapid production and an overactivity of
osteoclasts. Thefactthatanti-RANKLantibodyworkedeffectively
and quickly in patients 9 and 10 would support this latter
hypothesis; however, RANKL serum levels were not assessed and
these two hypotheses are not mutually exclusive.
The molecular analysis of these five new patients led to the
identification offivenovelmutationsintheTNFRSF11Agene:two
missense mutations (p.Ala134Val and p.Asp148Val), two non-
sense (p.Glu83X and p.Cys124X), and a single-nucleotide
insertion leading to frameshift and premature termination
(p.Arg110ProfsX52). They are all located in the extracellular
region of the protein, in particular, p.Ala134Val and p.Asp148Val
areinthefourthcysteinerichdomain(CRD4)which,accordingto
the recent crystallographic model of the murine protein,
(20,21) is
not directly involved in the binding of the ligand. However,
the mutated residues appeared to be strongly conserved in
evolution, so it could be suggested that amino acid substitutions
at these positions might alter the folding of the ectodomain
and, as a consequence, the interaction with RANKL. A similar
hypothesis has been raised for three mutations we reported
in our previous work,
(4) namely, p.Gly53Arg, p.Arg170Gly and
p.Cys175Arg.
(20,21)
The two nonsense mutations and the insertion are predicted
to lead to the production of truncated forms of RANK protein,
lacking the entire transmembrane and intracellular domains. As
hypothesized by Crockett and colleagues
(5) for other truncating
mutations previously identified in TNFRSF11A, the nonsense-
mediated mRNA decay process is likely to lead to the destruction
of a significant proportion of the mRNA molecules transcribed
from these mutated alleles resulting in reduced levels of
TNFRSF11A expression. However, for these novel mutations in
the N-terminal domain, the possibility of reinitiation from a
downstream methionine codon cannot be excluded, as has
previously been reported in several diseases.
(22–24) The putative
shorter transcript could maintain a partial activity and be
responsible for the milder phenotype of patient 9, who is
homozygous for the mutation p.Arg110ProfsX52. However, the
analysis at theprotein level wasnotpossible eitherinthis patient
or in patient 11, who is compound heterozygous for p.Glu83X
and p.Cys124X mutations. In addition preliminary in vitro
experiments using expression constructs bearing the mutant
sequences were inconclusive (data not shown); therefore, this
possibility remains completely speculative.
In conclusion, RANK-dependent ARO is confirmed to benefit
from HSCT, although patients seem to be particularly prone to
hypercalcemia in the post-HSCT period, especially when HSCT
is carried out at an older age. Defects of the humoral immune
system can be present, but apparently not as severe as in
the corresponding knockout murine model. These data add to
the clinical and molecular heterogeneity of human ARO and
350 PANGRAZIO ET AL. Journal of Bone and Mineral Researchfurther confirm the important role of a precise molecular
diagnosis with respect to therapy.
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